Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Cantor Fitzgerald Reiterates Overweight on Akero Therapeutics

Author: Benzinga Newsdesk | June 20, 2024 01:18pm
Cantor Fitzgerald analyst Prakhar Agrawal reiterates Akero Therapeutics (NASDAQ:AKRO) with a Overweight.

Posted In: AKRO